Log in to save to my catalogue

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) as a therapeutic target to prevent retinal vasoper...

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) as a therapeutic target to prevent retinal vasoper...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4932924

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) as a therapeutic target to prevent retinal vasopermeability during diabetes

About this item

Full title

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) as a therapeutic target to prevent retinal vasopermeability during diabetes

Publisher

United States: National Academy of Sciences

Journal title

Proceedings of the National Academy of Sciences - PNAS, 2016-06, Vol.113 (26), p.7213-7218

Language

English

Formats

Publication information

Publisher

United States: National Academy of Sciences

More information

Scope and Contents

Contents

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) hydrolyses oxidized low-density lipoproteins into proinflammatory products, which can have detrimental effects on vascular function. As a specific inhibitor of Lp-PLA₂, darapladib has been shown to be protective against atherogenesis and vascular leakage in diabetic and hypercholesterolemic animal m...

Alternative Titles

Full title

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) as a therapeutic target to prevent retinal vasopermeability during diabetes

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4932924

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4932924

Other Identifiers

ISSN

0027-8424

E-ISSN

1091-6490

DOI

10.1073/pnas.1514213113

How to access this item